Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link BK, Weiner GJ. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood. 2011 Sep 22;118(12):3347-9. Epub 2011 Jul 18. PubMed PMID: 21768303 PMCID:PMC3179401.

Wang SY, Veeramani S, Racila E, Cagley J, Fritzinger DC, Vogel CW, St John W, Weiner GJ. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood. 2009 Dec 17;114(26):5322-30. Epub 2009 Oct 5. PubMed PMID: 19805620; PubMed Central PMCID:PMC2796137.

Wang SY, Weiner G. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther. 2008 Jun;8(6):759-68. Review. PubMed PMID:18476787.

Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood. 2008 Feb 1;111(3):1456-63. Epub 2007 Nov 16. PubMed PMID: 18024795; PubMed Central PMCID: PMC2214766.

Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, Marquis D, Ondek B, Wooldridge JE, Smith BJ, Breitmeyer JB, Weiner GJ. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2006 Oct 15;108(8):2648-54. Epub 2006 Jul 6. PubMed PMID: 16825493; PubMed Central PMCID: PMC1895597.